Gene Bridges granted Korean Patent for Recombineering Technology
Gary Stevens, CEO of Gene Bridges GmbH, commented: 'Recombineering is the technology of choice in DNA engineering and is used worldwide in industry and academia. In addition to the patents already granted Gene Bridges, this forms a part of the strong intellectual property position Gene Bridges is building worldwide. Korea has an important and growing life sciences sector and we look forward to working with the leading institutes and companies there.'
Red/ET is a method for DNA engineering. According to the company, recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.